Open an account

NanoViricides

NNVC · NYSE American

$1.48+$0.18 (+13.85%)TodayMarket closed ·
Prev close $1.30

About NNVC

The company is headquartered in Shelton, Connecticut and currently employs 7 full-time employees. The company went IPO on 2004-08-12.

Employees
7
Headquarters
Shelton, Connecticut
Listed
Aug 12, 2004
Sector
Health Care
Industry
Biotechnology
Website
nanoviricides.com

NNVC key statistics

Market cap
37.78M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
441.37K
Volume
464.10K
Open price
$1.30
High today
$1.51
Low today
$1.30
52 Week high
$2.23
52 Week low
$0.85

NanoViricides (NNVC) at a glance

NanoViricides (NNVC) last traded at $1.48, with a market cap of 37.78M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.30 and $1.51. The current price is 13.8% above the day's low and 2.0% below its high.

Volume so far is 464.10K shares, in line with the average of 441.37K shares a day.

Over the past year NanoViricides has ranged from $0.85 to $2.23, and now sits 46% of the way up that range.

NanoViricides met or beat analyst EPS estimates in 8 of the last 8 quarters. In Q4 FY26 it reported -$0.10 per share against an estimate of -$0.102.

The average analyst price target is $6.12, 313.5% above the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 1 analyst rating say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 5 analystsAvg $6.12
Low
$6.06
Now
$1.48
High
$6.30

NNVC earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 8 of the last 8 quarters, by 14.7% on average.

  1. Q3 FY23: reported -$0.15 per share against an estimate of -$0.1734
  2. Q1 FY24: reported -$0.17 per share against an estimate of -$0.1734
  3. Q2 FY24: reported -$0.18 per share against an estimate of -$0.1938
  4. Q3 FY24: reported -$0.16 per share against an estimate of -$0.1938
  5. Q4 FY24: reported -$0.19 per share against an estimate of -$0.204
  6. Q1 FY26: reported -$0.10 per share against an estimate of -$0.1836
  7. Q2 FY26: reported -$0.11 per share against an estimate of -$0.1428
  8. Q4 FY26: reported -$0.10 per share against an estimate of -$0.102

NNVC news

  • Press releaseACCESS Newswire

    NanoViricides Provides Additional Details on the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola as the Outbreak Continues to Expand and Has Taken Over 4,000 Lives

  • Press releaseACCESS Newswire

    NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Is In Phase II Clinical Trials

  • Press releaseACCESS Newswire

    Clinical Trial of the Oral Drug NV-387 to Treat Ebola Has Started Enrollment and Dosing of Patients Last Week (on or about September 23rd), Says NanoViricides

  • Press releaseACCESS Newswire

    Phase II Clinical Trial of NV-387 as a Treatment for Monkeypox (MPox) Has Begun in DRC, Announces NanoViricides

  • Press releaseACCESS Newswire

    Clinical Trial of the Oral Drug NV-387 to Treat Ebola to Start Next Week, Hoping to Reduce Fatalities and Spread, As the Largest Ebola Outbreak is Expanding in 
DR Congo with 48% Crude Fatality Rate, Says NanoViricides

  • Press releaseGlobe Newswire

    A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat

  • Press releaseACCESS Newswire

    Clinical Trial for an Oral Drug to Treat Ebola is Registered in the Pan African Clinical Trials Database and is Ready to Go, As the Largest Ebola Outbreak Continues to Expand in DR Congo

  • World Health Organization Director General Determined That The Ebola Epidemic In DRC Still Meets Criteria Of Public Health Emergency Of International Concern, But Not Those Of A Pandemic Emergency

Similar companies

Companies in the same industry as NanoViricides

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.